Acute Myeloid Leukemia Clinical Trial

A Phase 1 Trial of CD33xCD3 BsAb in Pediatric Patients With Relapsed or Refractory Acute Myeloid Leukemia

Summary

Pediatric patients (<21 years at study entry) with relapsed or refractory acute myeloid leukemia (AML) will be treated with CD33*CD3 a bispecific antibody to investigate the safety and tolerability of the drug.

View Full Description

Full Description

This is an open label, first in human dose escalation trial in pediatric patients with relapsed or refractory acute myeloid leukemia to assess the safety and tolerability of increasing doses of CD33xCD3 BsAb administered subcutaneously.

A modified Bayesian Optimal Interval Design (mBOIN) design will be applied. The trial will start with accelerated titration using single patient cohorts until one grade ≥2 AE not clearly associated to underlying disease, thereafter the trial will continue with mBOIN titration.

View Eligibility Criteria

Eligibility Criteria

Inclusion Criteria:

Signed informed consent from legal guardian(s), patient and/or child obtained in accordance with local regulations. Pediatric patients must provide assent as required by local regulations
Age ≥2 years, and ≤21 years, and a minimum body weight of ≥11 kg
Histologically confirmed relapsed or refractory AML (except acute promyelocytic leukemia) with no therapeutic options that may provide clinical benefit. Disease burden ≥5.0% in the bone marrow meets definition for enrollment.
Karnofsky performance status ≥50 for ≥16 years / Lansky performance status ≥50 for <16 years
White blood cells (WBC) ≤25 x 109/L (may receive hydroxyurea to bring WBC count down prior to first dose of CD33xCD3 BsAb and during Cycle 1 or low dose cytarabine up to 48 h prior to first dose of CD33xCD3 BsAb)

Central Nervous System (CNS) disease as per Children's Oncology Group

Patients must have the status of CNS1 and no clinical signs or neurologic symptoms suggestive of CNS leukemia, such as cranial palsy
Patients with CNS3 or CNS2 status may receive antecedent intrathecal chemotherapy to achieve CNS1 status prior to trial entry
Patients with a history of CNS chloromatous disease are required to have no radiographic evidence of disease prior to enrollment
Has acceptable liver and kidney laboratory values
Patient must have recovered from acute toxic effects of prior anti-cancer therapies prior to first dose of CD33xCD3 BsAb

Exclusion Criteria:

History of uncontrolled seizure. If on anti-convulsant and/or seizures are well controlled as per treating physician enrollment is acceptable
Acute promyelocytic leukemia with PML-RARA genetic abnormality according to WHO classification or t(15;17)
Isolated extramedullary AML
Clinically significant graft-versus-host disease (GvHD) secondary to prior allogeneic transplantation. No immunosuppressive therapy for ≥14 days prior to first dose, except for topical corticosteroids for minor rash (<5% of BSA) or adrenal replacement therapy
Patient known to have one of the following genetic syndromes: Bloom syndrome, ataxia-telangiectasia, Fanconi anemia, Nijmegen breakage syndrome, Kostmann syndrome, Shwachman Diamond syndrome or any known bone marrow failure syndrome where increased risk for toxicity may be expected as judged by the Investigator

Treatment with another investigational agent under the following conditions:

Within two weeks (four weeks for biologics) before first administration of CD33xCD3 BsAb; or
Patient has persistent toxicities from prior anti-leukemic therapies which are determined to be relevant by the Investigator

Study is for people with:

Acute Myeloid Leukemia

Phase:

Phase 1

Estimated Enrollment:

36

Study ID:

NCT05077423

Recruitment Status:

Recruiting

Sponsor:

Y-mAbs Therapeutics

Check Your Eligibility

Let’s see if you might be eligible for this study.

What is your age and gender ?

Submit

There are 13 Locations for this study

See Locations Near You

Children's of Alabama/University of Alabama at Birmingham
Birmingham Alabama, 35233, United States
Children's Hospital of Orange County
Orange California, 92868, United States
UCSF Benioff Children's Hospital
San Francisco California, 94158, United States
Children's National Hospital
Washington District of Columbia, 20010, United States
Riley Hospital for Children - Indiana University
Indianapolis Indiana, 46202, United States
Dana-Farber Cancer Institute
Boston Massachusetts, 02215, United States
University of Minnesota/Masonic Cancer Center
Minneapolis Minnesota, 55455, United States
Washington University School of Medicine
Saint Louis Missouri, 63110, United States
Memorial Sloan Kettering Cancer Center
New York New York, 10065, United States
Cincinnati Children's Hospital Medical Center
Cincinnati Ohio, 45229, United States
Children's Hospital of Philadelphia
Philadelphia Pennsylvania, 19104, United States
UPMC Children's Hospital of Pittsburgh
Pittsburgh Pennsylvania, 15224, United States
St Jude Children's Research Hospital
Memphis Tennessee, 38105, United States

How clear is this clinincal trial information?

Study is for people with:

Acute Myeloid Leukemia

Phase:

Phase 1

Estimated Enrollment:

36

Study ID:

NCT05077423

Recruitment Status:

Recruiting

Sponsor:


Y-mAbs Therapeutics

How clear is this clinincal trial information?

×

Introducing, the Journey Bar

Use this bar to access information about the steps in your cancer journey.